rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BYSI
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
      Nov 13Yahoo FinanceBYSI
      BeyondSpring Divests China Assets, Refocuses on Data Partnerships

      Detailed price information for Beyondspring Inc (BYSI-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailBYSI
      BeyondSpring Secures FDA Fast Track Designation for Plinabulin as DUBLIN-4 Phase 3 Trial Advances

      BeyondSpring received FDA Fast Track designation for Plinabulin plus docetaxel in post-ICI non-squamous NSCLC and announced a strategic transaction designed to reduce the cash required to advance its global Phase 3 DUBLIN-4 trial toward a prespecified interim analysis. Key Investor TakeawaysBeyondSpring (NASDAQ:BYSI) received FDA Fast Track designation for Plinabulin plus docetaxel in advanced or metastatic non-squamous NSCLC following prior anti-PD-(L)1 therapy and platinum chemotherapy.

      Sep 29Yahoo FinanceBYSI
      FDA grants fast track status to BeyondSpring’s lung cancer drug
      Sep 29Investing.comBYSI
      BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
      Sep 29Yahoo FinanceBYSI
      BeyondSpring Faces Nasdaq Noncompliance Over Minimum Bid Price

      Detailed price information for Beyondspring Inc (BYSI-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailBYSI

      This is the newest page. Registered accounts read further back.